United Therapeutics Europe

Semaglutide (OZEMPIC) is a glucagon-like peptide-1 (GLP-1) receptor agonist currently under investigation by United Therapeutics Europe Ltd for cardiomyopathy, a disease characterized by weakened heart muscle function. The program, designated internal code 22-000522, is in Phase 2 development with an active status as of the latest milestone dated 6 March 2026. Semaglutide is administered as a solution and is classified within the alimentary tract and metabolism therapeutic category (A10).

Semaglutide is already approved globally under the brand name OZEMPIC for diabetes management. The regulatory landscape shows approvals in Australia (first listed July 2020, with subsequent listings through June 2025), the European Union (multiple EMA product numbers with authorisation dates in March 2026), Japan (approved March 2023), and the United States (multiple NDA applications approved). The cardiomyopathy indication represents a novel therapeutic application beyond the drug's established diabetes indication.

The Phase 2 trial for cardiomyopathy (NCT05371496) represents an expansion of semaglutide's clinical utility into cardiovascular disease. This development aligns with emerging evidence suggesting GLP-1 receptor agonists may have cardioprotective properties. The latest milestone on 6 March 2026 indicates ongoing trial activity, though specific endpoint data and trial results have not yet been disclosed. Expected next milestones and peak sales projections for this indication remain undisclosed.

Cardiomyopathy affects millions globally and remains a leading cause of heart failure, with limited pharmacological options beyond standard heart failure therapies. The investigation of semaglutide in this indication addresses a significant unmet medical need, as GLP-1 receptor agonists have demonstrated cardiovascular benefits in diabetes populations and may offer novel mechanisms in non-diabetic cardiomyopathy.

Market relevance is substantial given the large patient population with heart failure and cardiomyopathy, combined with the commercial success of semaglutide in diabetes and obesity indications. A positive Phase 2 outcome could support label expansion and open a new therapeutic category for GLP-1 agonists, potentially differentiating semaglutide from competitors in the cardiovascular space.

Competitive positioning is notable because the identified competitors (ONGLYZA, ACTOS, FORXIGA, TRAJENTA, NESINA, VIPIDIA, ZYNQUISTA, SAXENDA, QTRILMET, INVOKANA, REPAGLINIDE SUN, TRAZEC) are primarily diabetes and metabolic agents with approved status. Few have established cardiomyopathy indications, suggesting semaglutide could capture first-mover advantage if Phase 2 data support efficacy. The patient population includes both diabetic and non-diabetic cardiomyopathy patients, expanding addressable market beyond traditional GLP-1 user bases.

Drug Class: Glucagon-like peptide-1 (GLP-1) receptor agonist.

Modality: Small molecule (as classified in the program data).

Route of Administration: Solution (subcutaneous injection).

Therapeutic Classification: Alimentary tract and metabolism (ATC code A10).

Mechanism of Action: Not yet disclosed for the cardiomyopathy indication; however, semaglutide is established as a GLP-1 receptor agonist with known effects on glucose homeostasis and emerging evidence of cardioprotective properties.

Target: Not yet disclosed for this program.

Related Therapies: Competitors include other diabetes agents (ONGLYZA—saxagliptin, TRAJENTA—linagliptin, NESINA—alogliptin, VIPIDIA—vildagliptin, ZYNQUISTA—canagliflozin), insulin secretagogues (REPAGLINIDE SUN), thiazolidinediones (ACTOS—pioglitazone), SGLT2 inhibitors (FORXIGA—dapagliflozin, INVOKANA—canagliflozin), and GLP-1 agonists (SAXENDA—liraglutide).

First Approval: Semaglutide (OZEMPIC) was first approved in Australia on 1 July 2020; approved in Japan in March 2023; approved in the European Union with multiple authorisations in March 2026; and approved in the United States under multiple NDAs.

Patent Status: Not yet disclosed.

United States: Semaglutide (OZEMPIC) is approved via multiple NDAs (209637, 213051, 213182, 215256, 218316) and ANDA220314 (generic). Sponsors include Novo Nordisk Inc and Apotex Inc. Regulatory status for the cardiomyopathy indication is not yet disclosed.

European Union: Semaglutide is approved under multiple EMA product numbers (EMEA/H/C/004174, EMEA/H/C/004953, EMEA/H/C/005422, EMEA/H/C/006426) with Marketing Authorisation Holder Novo Nordisk A/S. Authorisation dates include 26 March 2026 and 30 March 2026. Cardiomyopathy indication regulatory pathway not yet disclosed.

Japan (PMDA): Semaglutide approved March 2023. Cardiomyopathy indication status not yet disclosed.

Australia (TGA): Semaglutide approved and listed on the Australian Register of Therapeutic Goods (ARTG) with PBS codes 12075M, 12080T, 14149Q, 14163K, 14844G, 14846J, 15311W, 15322K. First listing 1 July 2020; subsequent listings through June 2025. Sponsor: Novo Nordisk Pharmaceuticals Pty. Limited. Cardiomyopathy indication status not yet disclosed.

China (NMPA): Semaglutide is in clinical trials (NCT05877547). Regulatory approval status for any indication not yet disclosed.

Cardiomyopathy Indication: Expected loss of exclusivity date, regulatory pathway, and approval timeline not yet disclosed.

Strategic Implications: United Therapeutics Europe Ltd's investigation of semaglutide in cardiomyopathy represents a label expansion strategy leveraging an already-approved asset into a new therapeutic area with significant unmet medical need. This approach reduces development risk compared to novel molecule programs while potentially capturing first-mover advantage in a GLP-1 agonist cardiomyopathy indication.

Competitive Implications: If Phase 2 data support efficacy, semaglutide could differentiate from SGLT2 inhibitors (FORXIGA, INVOKANA) and other GLP-1 agonists (SAXENDA) by establishing a dedicated cardiomyopathy indication. The lack of disclosed cardiomyopathy programs among identified competitors suggests limited near-term competitive pressure, though this may reflect incomplete disclosure rather than absence of development activity.

Future Catalysts: Phase 2 trial completion and data readout (expected milestone timing not yet disclosed) represent the primary near-term catalyst. Positive efficacy and safety data could support Phase 3 initiation and regulatory submissions across major markets. Negative or inconclusive Phase 2 results would likely halt further development in this indication.

Expected Milestones: Phase 2 trial enrollment completion, interim or final efficacy/safety analysis, and potential Phase 3 initiation represent key upcoming milestones. Regulatory interactions with FDA, EMA, PMDA, and NMPA regarding cardiomyopathy indication pathway are not yet disclosed. Peak sales projections and commercial strategy for this indication remain undisclosed.